chemotherapy |
Dose, frequency and no.of cycles |
Adverse
events |
Cisplatin (P)
|
(Every 3 weeks, RT days 1, 22, 43)
P: 100 mg/m2 on day 1
|
(Grade 3–5 increased frequencies,
compared with control arm,
occurring in more than 10% of patients)
Nausea/vomiting (12–40%) Neutropenia
(13%) Infection (12%) Peripheral
neuropathy (10%)
Nausea/vomiting (12–40%)
Neutropenia (13%)
Infection (12%)
Peripheral neuropathy (10%)
|
Cetuximab
|
Loading dose: 400 mg/m2 (4–10 days prior to RT)
Maintenance: 250 mg/m2 weekly during RT)
|
(Grade 3–5 increased
frequencies)
Infusion reactions (3%)
Acneiform rash (17%)
Hypomagnesemia
|
TPF (TAX 324)
Docetaxel (T)
Cisplatin (P)
5-FU (F)
|
(Every 3 weeks for 3 cycles)
T: 75 mg/m2 on day 1
P: 100 mg/m2 on day 1
F: 1000 mg/m2 CI days 1–4
|
(Grade 3 or 4 frequencies)
Neutropenia (33%)
Infection (7%)
Febrile neutropenia (5%)
|
TPF (European)
Docetaxel (T)
Cisplatin (P)
5-FU (F)
|
(Every 3 weeks for 4 cycles)
T: 75 mg/m2 on day 1
P: 75 mg/m2 on day 1
F: 750 mg/m2 by CI days 1–5
|
(Grade 3 or 4 frequencies)
Neutropenia (77%)
Alopecia (12%)
Infection (7%)
Febrile neutropenia (5%)
|
Cisplatin (P)
5-FU (F)
|
P: 100 mg/m2 on day 1
F: 1000 mg/m2 by CI days 1–5
|
Nausea/vomiting (7–14%)
Hematologic (52–56%)
Infection (5–6%)
Peripheral neuropathy (1–4%)
|